NSF Awards NOVA’s Biotechnology Program $550,000 for NOBLE Project

The NOVA Biotechnology and Leadership in Education (NOBLE) Project will be funded by the National Science Foundation with more than $550,000 over the next three years. The goal of the NOBLE Project is to revitalize and grow the biotechnology program. The NOBLE Project seeks to recruit students throughout the entire NOVA service area, particularly minorities in STEM, veterans and dual-enrollment students. The NOBLE Project will include faculty from the Alexandria and Manassas campuses.

The goal of the NOBLE Project is to train students in technical and professional skills to increase their competitiveness in the biotechnology job market. Students will gain additional key experiences by attending scientific conferences and connecting with scientific organizations. Importantly, the grant will provide funds for paid internships at local biotechnology companies. Work will begin this summer. Interested students should contact Xin Zhou at or David Fernandez at

The principle investigator (PI) of this project, Dr. David Fernandez, thanks Dr. Eun-Woo Chang, vice president of academic affairs and chief academic office; Dr. Xin Zhou, NOVA biotechnology program head; Dr. Maggie Emblom-Callahan, interim dean of MSTB Alexandria and Dr. Diane Mucci, Annandale Campus provost, for their guidance and vision in crafting this project.

Recent News


ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs

ATCC, the world’s premier biological materials management and standards organization, today announced a seven-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to continue the management of the BEI Resources Program. NIAID has made an initial award of over $21.5 million, with further funding


Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck’s oncology clinical studies. “We’re proud to be working with Merck because being a champion for health equity through inclusive research


cultivate(MD) Capital Funds LP Announces Investment into Nanochon

cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator. Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring cartilage restoration.  Nanochon’s Chondrograft™ replaces lost or damaged